GlassScriptPhysician profile
Daniel Hansford Kellum
NPI 1205820990
$16,963.09
in general payments reported to CMS, 2019-2025
76 companies · $1,789 in 2025
The $1,789 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,289 · 2020: $2,003 · 2021: $2,170 · 2022: $2,540 · 2023: $3,175 · 2024: $1,998 · 2025: $1,789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,373 · Travel and Lodging: $348 · Education: $241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,372.81 |
| Travel and Lodging | $348.10 |
| Education | $240.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,782.88 | 2020-2025 | |
| Amgen INC. | $1,508.94 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $1,376.59 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Amarin Pharma, INC. | $904.22 | 2019-2022 | |
| Lilly USA, LLC | $867.33 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Allergan, INC. | $626.84 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $606.35 | 2022-2025 | |
| Pfizer INC. | $588.84 | 2019-2025 | |
| Astellas Pharma US INC | $551.36 | 2019-2024 | Myrbetriq, Veozah |
| Glaxosmithkline, LLC. | $479.87 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $445.87 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $436.39 | 2019-2023 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $364.16 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $348.14 | 2022-2024 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $322.86 | 2019-2024 | Farxiga, Breztri |
Show all 75 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kellum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.